MCL1 and prostate cancer: Additionally, direct and indirect knockdown of MCL-1 has been shown to sensitize prostate cancer cells to anti-mitotic agents, including docetaxel, suggesting that MCL-1 targeting may also synergize with chemotherapy [53,223,224].